Teva Pharmaceuticals USA is the leading generic pharmaceutical company, marketing products from a wide range of therapeutic areas including cardiovascular, anti-infective, CNS, anti-inflammatory, oncolytic, antidiabetic, analgesic, dermatology, respiratory, and women's healthcare. Dosage forms include tablets and capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. Teva USA products are marketed to chains, wholesalers, distributors and government agencies, as well as in health systems and oncology settings. Teva USA has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry. The company's mission is to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals.

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

Pharmaxis has an ax to grind with chronic respiratory and autoimmune diseases. The Australian company researches, develops, and markets therapeutic pharmaceutical products to combat these and other illnesses. Pharmaxis has received approval to market asthma treatment Aridol in select regions. The company has research and development programs for additional disease targets such as cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and pulmonary fibrosis. Pharmaxis acquired respiratory therapeutics developer TOPIGEN Pharmaceuticals in 2010, adding to Pharmaxis' roster of potential treatments for respiratory disorders including asthma and COPD.

Protein Polymer Technologies, Inc. company was founded in 1988 and is based in San Diego, California. Protein Polymer Technologies, Inc., a biotechnology company, engages in the research, development, and production of bio-active devices to improve medical and surgical outcomes. The company, through its proprietary technology, produces molecular weight polymers that can be processed into a range of material forms, such as gels, sponges, films, and fibers. It also focuses on developing protein polymers that are used in products for tissue augmentation, tissue adhesives and sealants, and drug delivery devices. The company also develops and offers surgical tissue sealants that include tissue adhesives and sealants; wound healing and tissue regeneration products, including fabric dressings, synthetic materials, and biological materials; and urethral bulking agent that relieves female stress incontinence. In addition, it develops coating technology that modifies and improves surface properties of traditional biomedical devices.

ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California. ISTA Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company with products and product candidates for the treatment of inflammation, ocular pain, glaucoma, allergy and dry eye. The Company has three products available for sale in the United States: Xibrom, (bromfenac ophthalmic solution) for the treatment of inflammation and pain following cataract surgery, Istalol, (timolol maleate ophthalmic solution) for the treatment of glaucoma, and Vitrase (hyaluronidase for injection) for use as a spreading agent. The Company also has several product candidates in various stages of development. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma.

Cephalon, Inc. was founded in 1987 and is headquartered in Frazer, Pennsylvania. Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The company's pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa.

Compugen Ltd. company was founded in 1993 and is based in Tel Aviv, Israel. Compugen Ltd. (Compugen) is engaged in drug and diagnostic product candidate discovery and the commercialization of such candidates through early-stage licensing and co-development agreements. The Company’s business is focused on developing and using predictive computer-based discovery platforms to discover therapeutic drug candidates and diagnostic biomarker candidates. The Company uses experimental biological processes to validate product candidates discovered by its predictive platforms. Its initial discovery platforms focused mainly on cancer, cardiovascular and immune-related diseases. In July 2008, Compugen announced results from an in vivo study of CGEN-25007, a peptide antagonist of the gp96 protein. The data indicate that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.

LEO Pharma- UK lays claim to being king of the dermatology drug jungle in the UK. LEO Pharma UK company, which is the British arm of Denmark's LEO Pharma, handles the sales and marketing LEO's dermatological and critical care pharmaceutical products in the UK. LEO Pharma UK also has a growing medical department which conducts clinical studies on behalf of the group. The parent company focuses on topical prescription medications for psoriasis and other dermatological conditions. The group's lead critical care products include anticoagulant heparin (derived from porcine mucosa) and vitamin D.

DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts. DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The BLU-U is used without Levulan to treat moderate inflammatory acne vulgaris and general dermatological conditions. The company is also developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, ClindaReach, Meted, and Psoriacap products.

Emergent BioSolutions Inc. company was founded in 1998 and is based in Rockville, Maryland. mergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The company's earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.